Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis

Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis

We compared progression-free survival (PFS) and overall survival (OS) among 292 metastatic renal cell carcinoma (mRCC) patients either undergoing nephrectomy (Nx, 61.6%) or not (non-Nx, 38.4%), stratified according to the MSKCC and Heng risk models, treated with either immunotherapy (IT, 45.2%) or t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2018-02, Vol.8 (1), p.2974-8, Article 2974
Hauptverfasser: Kim, Sung Han, Jeong, Kyung-Chae, Joung, Jae Young, Seo, Ho Kyung, Lee, Kang Hyun, Chung, Jinsoo
Format: Artikel
Sprache:eng
Schlagworte:
631/250/251/1567
692/4025/2021
692/4028/546
692/4028/67/589/1588/1351
Humanities and Social Sciences
Immunotherapy
Kidney cancer
Metastases
Metastasis
multidisciplinary
Nephrectomy
Renal cell carcinoma
Science
Science (multidisciplinary)
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We compared progression-free survival (PFS) and overall survival (OS) among 292 metastatic renal cell carcinoma (mRCC) patients either undergoing nephrectomy (Nx, 61.6%) or not (non-Nx, 38.4%), stratified according to the MSKCC and Heng risk models, treated with either immunotherapy (IT, 45.2%) or targeted therapy (TT, 54.8%) between 2000 and 2015. During the follow-up duration of 16.6 months, PFS/OS of the Nx (6.0/30 months) and non-Nx (3.0/6.0 months) groups were significantly different despite differences among baseline parameters (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-20822-2